SLC34A2 Antibody (upifitamab) [Janelia Fluor® 585]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28057JF585
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Janelia Fluor 585
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # upifitamab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
NaPi2b / SLC34A2
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for SLC34A2 Antibody (upifitamab) [Janelia Fluor® 585]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SLC34A2
Alternate Names
NAPI-3B, NPTIIb, sodium/phosphate cotransporter 2B, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b
Gene Symbol
SLC34A2
Additional SLC34A2 Products
Product Documents for SLC34A2 Antibody (upifitamab) [Janelia Fluor® 585]
Product Specific Notices for SLC34A2 Antibody (upifitamab) [Janelia Fluor® 585]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...